Amneal Pharmaceuticals (AMRX) Short-Term Debt issuances: 2017-2025
Historic Short-Term Debt issuances for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Mar 2025 value amounting to $218.0 million.
- Amneal Pharmaceuticals' Short-Term Debt issuances rose 354.17% to $218.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $385.0 million, marking a year-over-year increase of 105.88%. This contributed to the annual value of $48.0 million for FY2024, which is 78.08% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Short-Term Debt issuances stood at $218.0 million for Q1 2025, which was up 354.17% from $48.0 million recorded in Q1 2024.
- Over the past 5 years, Amneal Pharmaceuticals' Short-Term Debt issuances peaked at $218.0 million during Q1 2025, and registered a low of $10.0 million during Q3 2023.
- Its 3-year average for Short-Term Debt issuances is $80.8 million, with a median of $64.0 million in 2023.
- Per our database at Business Quant, Amneal Pharmaceuticals' Short-Term Debt issuances tumbled by 76.47% in 2023 and then surged by 354.17% in 2025.
- Quarterly analysis of 4 years shows Amneal Pharmaceuticals' Short-Term Debt issuances stood at $85.0 million in 2022, then plummeted by 76.47% to $109.0 million in 2023, then crashed by 40.00% to $48.0 million in 2024, then spiked by 354.17% to $218.0 million in 2025.
- Its Short-Term Debt issuances stands at $218.0 million for Q1 2025, versus $48.0 million for Q1 2024 and $109.0 million for Q4 2023.